Peptide Monograph
AOD-9604
Advanced Obesity Drug — HGH Fragment 176-191
At a Glance
Mechanism of Action
AOD-9604 is a synthetic analog of the C-terminal fragment of human growth hormone (hGH), corresponding to amino acids 176–191, with a tyrosine substitution at position 182. This region of the GH molecule has been identified as the lipolytic domain, responsible for the fat-metabolizing activity of growth hormone, while being distinct from the regions responsible for GH's growth-promoting and diabetogenic effects.[1]
The primary mechanism of AOD-9604 involves stimulation of lipolysis (the breakdown of stored triglycerides into free fatty acids and glycerol) and inhibition of lipogenesis (the synthesis of new fat from non-lipid substrates). In vitro studies using adipose tissue explants have demonstrated that AOD-9604 enhances lipolytic activity in a dose-dependent manner, comparable to the lipolytic effect of full-length hGH.[2]
AOD-9604 is thought to act, at least in part, through modulation of beta-3 adrenergic receptor signaling in adipose tissue. The beta-3 adrenergic receptor is expressed predominantly on adipocytes and plays a key role in regulating fat metabolism. Activation of this receptor stimulates hormone-sensitive lipase (HSL) activity, promoting the hydrolysis of stored triglycerides. Ng et al. demonstrated that the lipolytic effects of the hGH 176–191 fragment are mediated through a pathway independent of the canonical GH receptor (GHR) signaling cascade, distinguishing it pharmacologically from full-length GH.[3]
Critically, AOD-9604 does not bind to or activate the growth hormone receptor in a manner that promotes IGF-1 production, skeletal growth, or insulin resistance. Animal studies have confirmed that AOD-9604 does not affect serum IGF-1 levels, fasting glucose, or insulin sensitivity at pharmacologically active doses, distinguishing it from the metabolic side-effect profile of full-length hGH therapy.[1][2]
Preliminary evidence also suggests that AOD-9604 may have chondroprotective properties. In vitro studies have demonstrated stimulation of proteoglycan and collagen synthesis in cartilage, raising the possibility of applications in osteoarthritis, though this mechanism is not yet well characterized.[4]
Evidence Summary
AOD-9604 has undergone Phase 2b clinical testing as an oral formulation for obesity, which failed to meet its primary efficacy endpoint. The injectable form used in the research community has not been evaluated in any published randomized controlled trial. The evidence base consists primarily of animal studies, in vitro work, and the failed oral formulation trial. All claims about injectable efficacy are extrapolated and should be evaluated with extreme caution.
Animal and In Vitro Studies
Heffernan et al. demonstrated that the hGH fragment 176–191 reduces body fat in obese mice without the growth-promoting or diabetogenic effects of full-length GH. Chronic treatment with the fragment led to significant reductions in body weight and adipose tissue mass compared to controls, with no effect on IGF-1 levels or glucose tolerance.[1]
Ng et al. further characterized the lipolytic mechanism, demonstrating that the 176–191 fragment stimulates lipolysis in both murine and human adipose tissue explants. The study confirmed that this activity is independent of the GH receptor and does not require the presence of the N-terminal somatogenic domain of GH.[3]
In vitro cartilage studies by Metabolic Pharmaceuticals showed that AOD-9604 stimulated proteoglycan synthesis in bovine cartilage explants, suggesting potential chondroprotective effects that could be relevant to osteoarthritis treatment.[4]
Human Clinical Data
Metabolic Pharmaceuticals Ltd. (Australia) conducted a Phase 2b randomized, double-blind, placebo-controlled clinical trial of oral AOD-9604 in approximately 300 obese subjects. The trial evaluated multiple dose levels of an oral formulation over 24 weeks. The primary endpoint was reduction in body weight compared to placebo. The trial failed to demonstrate statistically significant weight loss at any dose tested.[5]
Importantly, the oral formulation used in the Phase 2b trial may have had different pharmacokinetic properties than the subcutaneous injectable form. The low oral bioavailability of peptides in general raises questions about whether adequate systemic drug exposure was achieved in the oral trial. However, no published clinical trial has evaluated injectable AOD-9604, so the injectable route remains clinically unvalidated as well.
TGA (Australia) Classification
In 2010, the Australian Therapeutic Goods Administration (TGA) classified AOD-9604 as a complementary medicine ingredient based on safety data submitted by Metabolic Pharmaceuticals. This classification was based on the compound's safety profile, not on demonstrated clinical efficacy, and does not constitute therapeutic approval.[5]
Primary Uses (in Research)
Based on the available preclinical and limited clinical literature, AOD-9604 has been investigated for the following applications:
- Fat loss / lipolysis — Primary intended application. Preclinical data shows stimulation of lipolysis and inhibition of lipogenesis without growth-promoting or diabetogenic effects. However, the Phase 2b oral trial failed to demonstrate clinical efficacy for weight loss.[1][5]
- Body recomposition — Used in the research community for targeted fat reduction. Evidence is limited to animal models and self-reported anecdotal outcomes.[2]
- Cartilage repair / osteoarthritis — Emerging area of research based on in vitro studies showing stimulation of proteoglycan and collagen synthesis in cartilage. Clinical validation is absent.[4]
- Metabolic health — Theoretical application based on the dissociation of lipolytic effects from diabetogenic effects. Animal data suggests neutral effects on glucose metabolism, but human metabolic studies have not been conducted.[3]
Contraindications
No established human contraindications exist due to insufficient clinical data. The following precautions are based on the peptide's pharmacological mechanism and represent theoretical concerns informed by the broader GH-fragment literature:
- Pregnancy and lactation — No reproductive toxicology or teratogenicity studies have been conducted. No safety data exists for use during pregnancy or breastfeeding. Use is strongly discouraged.
- Active malignancy — Although AOD-9604 does not stimulate IGF-1 production like full-length GH, its effects on cellular proliferation pathways in cancer are unknown. Use is not recommended in patients with active cancer until safety data is available.
- Insufficient safety data — The overall human safety database for AOD-9604 is extremely limited. Individuals with significant comorbidities, organ dysfunction, or those taking multiple medications should exercise particular caution given the absence of safety and interaction data.
- Pediatric use — No safety or efficacy data exists for use in children or adolescents. Not recommended.
- Known hypersensitivity — Discontinue use if signs of allergic reaction (rash, urticaria, angioedema, dyspnea) develop.
Standard Protocols
The following protocols are derived from animal study dosing extrapolations and community-reported protocols. No injectable dosing regimen has been validated in human clinical trials. The oral formulation tested clinically failed to demonstrate efficacy. These should not be interpreted as medical prescriptions.
| Protocol | Route | Dose | Frequency | Duration |
|---|---|---|---|---|
| Fat loss (standard) | SubQ (abdominal fat) | 250 mcg | 1x daily (morning, fasted) | 8–12 weeks |
| Fat loss (higher dose) | SubQ (abdominal fat) | 500 mcg | 1x daily (morning, fasted) | 8–12 weeks |
| Targeted fat reduction | SubQ (local to target area) | 250 – 500 mcg | 1x daily | 8–12 weeks |
Common Stacks & Synergies
In the peptide research community, AOD-9604 is sometimes combined with other compounds aimed at body composition optimization. The following combinations are discussed but have no published human clinical evidence supporting their combined use:
- AOD-9604 + Ipamorelin — Ipamorelin stimulates GH release, while AOD-9604 provides targeted lipolysis without the growth-promoting effects. The rationale is complementary fat-loss mechanisms through separate pathways.
- AOD-9604 + BPC-157 — Combination sometimes used in body recomposition protocols, pairing AOD-9604's lipolytic effects with BPC-157's tissue-repair properties.
- AOD-9604 + CJC-1295/Ipamorelin — Triple stack combining GH secretagogues with AOD-9604 for enhanced fat loss. No evidence supports additive or synergistic effects.
- AOD-9604 + Frag 176-191 (unmodified) — Some protocols combine the modified (AOD-9604) and unmodified hGH fragment, though the pharmacological rationale for this combination is unclear.
Preparation & Administration
AOD-9604 is supplied as a lyophilized (freeze-dried) powder in vials, typically containing 2 mg or 5 mg of peptide. It must be reconstituted with bacteriostatic water (BAC water) before injection.
Reconstitution
For a standard 5 mg vial reconstituted with 2.5 mL of bacteriostatic water, each 0.1 mL (10 units on a standard insulin syringe) delivers 200 mcg. For a 250 mcg dose, draw 12.5 units (0.125 mL). For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.
Injection
Subcutaneous injections should be administered using a 29–31 gauge insulin syringe. The preferred injection site is the abdominal subcutaneous tissue, ideally near the target fat deposit. Injections are typically administered in the morning on an empty stomach, as food intake (particularly carbohydrates) may interfere with lipolytic signaling. Wait at least 20–30 minutes after injection before eating. Rotate injection sites to avoid lipodystrophy. For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.
Side Effects & Adverse Events
The adverse event profile described below is drawn from the oral Phase 2b trial, animal studies, and uncontrolled self-reports. The injectable form has not been evaluated in any controlled human trial. The true incidence and severity of side effects for injectable AOD-9604 cannot be established.
In the Phase 2b oral trial, AOD-9604 was generally well-tolerated at the doses tested. No significant drug-related serious adverse events were reported during the 24-week study period. The safety profile of the oral formulation appeared comparable to placebo.[5]
In animal studies, AOD-9604 did not produce the diabetogenic effects (impaired glucose tolerance, insulin resistance) associated with full-length GH, supporting its favorable metabolic safety profile at lipolytic doses.[1][2]
Self-reported side effects from community use (unverified, injectable form):
- Injection site redness, swelling, or mild pain (most commonly reported)
- Headache (occasionally reported)
- Mild nausea (infrequent)
- Localized skin irritation (infrequent)
The absence of systematic pharmacovigilance for injectable AOD-9604 means rare or delayed adverse effects could go undetected. The long-term consequences of chronic lipolysis stimulation via this pathway are unknown.
Drug Interactions
No formal drug interaction studies have been conducted with AOD-9604 in humans. The following theoretical interactions are based on the peptide's known pharmacological mechanisms:
- Beta-adrenergic agonists / antagonists — Given AOD-9604's proposed mechanism involving beta-3 adrenergic receptor modulation, concurrent use of beta-blockers (particularly non-selective agents) could theoretically attenuate its lipolytic effects. Beta-agonists (e.g., clenbuterol, albuterol) could theoretically produce additive lipolytic stimulation.[3]
- Growth hormone therapy — Concurrent use of exogenous GH with AOD-9604 would introduce overlapping lipolytic signaling plus the growth-promoting and diabetogenic effects absent from AOD-9604 alone. The net pharmacological effect of this combination is unpredictable.
- Insulin and oral hypoglycemics — Although AOD-9604 does not appear to affect glucose metabolism at standard doses, lipolysis produces free fatty acids that can impair insulin sensitivity at high levels. Diabetic patients should monitor glucose carefully.
- Thyroid hormones — Thyroid status influences basal metabolic rate and lipolysis. Hypo- or hyperthyroidism may modify the response to AOD-9604.
Storage & Handling
| Form | Condition | Stability |
|---|---|---|
| Lyophilized powder (sealed) | Refrigerated (2–8°C / 36–46°F) | Optimal; stable for months |
| Lyophilized powder (sealed) | Room temperature (below 25°C / 77°F), away from direct light | Stable for several weeks; refrigeration preferred |
| Reconstituted solution | Refrigerated (2–8°C / 36–46°F) | Use within 21–28 days |
| Reconstituted solution | Room temperature | Not recommended; use within 24 hours if unavoidable |
Do not freeze reconstituted solution. Protect from prolonged light exposure. If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Always use bacteriostatic water (not sterile water) for reconstitution to provide antimicrobial preservation for multi-dose use.
Legal & Regulatory Status
- FDA (United States) — Not approved for any indication. Not scheduled as a controlled substance. Sold under the research chemical designation "not for human consumption." No FDA applications for AOD-9604 are currently known to be pending.
- WADA (World Anti-Doping Agency) — AOD-9604 is explicitly listed on the WADA Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) as a growth hormone fragment. Athletes subject to anti-doping testing must not use this substance.
- Australia (TGA) — Classified as a complementary medicine ingredient by the TGA in 2010 based on safety data submitted by Metabolic Pharmaceuticals. This classification permits its use in listed complementary medicines in Australia but does not constitute therapeutic approval for any indication.[5]
- European Union — Not approved as a medicinal product. Generally available as a research chemical with regulatory status varying by member state.
- Legal gray area — In most jurisdictions, AOD-9604 is legal to purchase for research purposes but not legal to market for human therapeutic use.
Open Questions
The AOD-9604 evidence base has significant gaps. Key unresolved questions include:
- Oral vs. injectable bioavailability — The Phase 2b trial used an oral formulation. Peptide oral bioavailability is generally very low. Whether the failure of the oral trial reflects true lack of efficacy or inadequate drug exposure remains a critical open question.
- Clinical efficacy for injectable route — No controlled human trial has evaluated subcutaneous AOD-9604. The assumption that the injectable form is efficacious is based entirely on animal data and anecdotal reports.
- Long-term safety — The consequences of chronic, targeted lipolysis stimulation via the hGH fragment pathway are unknown. Effects on adipose tissue biology, hormonal signaling, and metabolic health with long-term use have not been studied.
- Mechanism validation in humans — While the lipolytic mechanism has been demonstrated in animal models and in vitro, confirmation that AOD-9604 produces meaningful lipolysis in human adipose tissue at achievable subcutaneous doses is lacking.
- Cartilage repair potential — Preliminary in vitro data suggesting chondroprotective effects requires animal model validation and eventually human clinical testing before any therapeutic claims can be considered.[4]
- Purity and quality control — As an unregulated research chemical, the purity, sterility, and accurate labeling of commercially available AOD-9604 products cannot be guaranteed.
Bibliography
- Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. "Increase of fat oxidation and weight loss in obese mice by chronic treatment with human growth hormone or a modified C-terminal fragment." Int J Obes Relat Metab Disord. 2001;25(10):1442-9. doi:10.1038/sj.ijo.0801740. PMID:11673764.
- Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. "Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism." Am J Physiol Endocrinol Metab. 2000;279(3):E501-7. doi:10.1152/ajpendo.2000.279.3.E501. PMID:10950816.
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Horm Res. 2000;53(6):274-8. doi:10.1159/000053183. PMID:11146367.
- Metabolic Pharmaceuticals Ltd. "AOD-9604: preclinical and clinical development summary." Company reports and regulatory submissions to the Australian Therapeutic Goods Administration (TGA), 2007–2010. Available via TGA public summary documents.
- Thompson D. "Metabolic Pharmaceuticals announces results of AOD-9604 Phase 2b obesity trial." Metabolic Pharmaceuticals Ltd. ASX Announcement, 2007. Available via Australian Securities Exchange filings.
- Ng FM, Bornstein J. "Hyperglycemic action of synthetic C-terminal fragments of human growth hormone." Am J Physiol. 1978;234(5):E521-6. doi:10.1152/ajpendo.1978.234.5.E521. PMID:645903.